Mod GRF 1-29 and GHRP-6 represent one of the most extensively evaluated peptide combinations in preclinical growth hormone secretagogue research. By simultaneously targeting distinct neuroendocrine receptor pathways, this dual-peptide regimen enables researchers to investigate amplified somatotropic signaling, receptor cross-talk, and ghrelin-mediated metabolic responses in vitro and in vivo models.
Mod GRF 1-29 and GHRP-6 represent one of the most extensively evaluated peptide combinations in preclinical growth hormone secretagogue research. By simultaneously targeting distinct neuroendocrine receptor pathways, this dual-peptide regimen enables researchers to investigate amplified somatotropic signaling, receptor cross-talk, and ghrelin-mediated metabolic responses in vitro and in vivo models.
Mod GRF 1-29 & GHRP-6 is a dual-peptide combination utilized in preclinical research to examine amplified growth hormone (GH) secretion through complementary receptor pathways. Mod GRF 1-29 acts as a GHRH receptor agonist, while GHRP-6 targets the growth hormone secretagogue receptor (GHS-R1a), producing a synergistic somatotropic release in laboratory models.
In physiological secretagogue studies, isolated stimulation of a single receptor type often yields sub-maximal endocrine release due to endogenous negative feedback loops and regulatory somatostatin tone. However, when laboratory researchers co-administer a GHRH analogue alongside a ghrelin receptor agonist, preclinical literature documents a supra-additive elevation in pituitary GH efflux.
PX1 Research supplies high-purity Mod GRF 1-29 and GHRP-6 specifically synthesized for rigorous laboratory evaluation. Both reagents undergo rigorous analytical verification to ensure reproducible experimental results across cell-culture assays and preclinical animal models.
Mod GRF 1-29 (also designated as Tetrasubstituted GRF 1-29 or CJC-1295 without DAC) is a 29-amino-acid synthetic peptide truncated from full-length human GHRH (1-44). To prevent rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) in serum, four specific amino acid substitutions are engineered into the backbone: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. These chemical modifications extend the biological half-life from approximately 5 minutes (native GHRH) to roughly 30 minutes in plasma assays, allowing sustained binding to the GHRH receptor on anterior pituitary somatotrophs.
Conversely, GHRP-6 (Growth Hormone Releasing Hexapeptide) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Incorporating unnatural D-amino acids confers substantial resistance against systemic endopeptidases. GHRP-6 acts as a potent agonist at the Growth Hormone Secretagogue Receptor type 1a (GHS-R1a), a G-protein coupled receptor (GPCR) distinct from the GHRH receptor.
When applied in dual-agonist experimental protocols, Mod GRF 1-29 initiates intracellular signaling via adenylate cyclase activation and cyclic AMP (cAMP) elevation. Concurrently, GHRP-6 triggers the phospholipase C (PLC) pathway, leading to inositol trisphosphate (IP3) production and intracellular calcium mobilization. This orthogonal signaling cascade forms the biochemical basis for the synergistic secretagogue response observed in published research peptides literature.
The primary objective of evaluating Mod GRF 1-29 & GHRP-6 together in preclinical models is to bypass somatostatic inhibition while maximizing intracellular secretagogue cascades. Somatostatin (SRIF) naturally acts as a potent brake on growth hormone secretion by hyperpolarizing pituitary somatotrophs and suppressing cAMP generation. In vitro pituitary cell culture studies demonstrate that GHS-R1a activation by hexapeptides like GHRP-6 actively antagonizes somatostatin receptor signaling.
Preclinical rodent trials indicate that while Mod GRF 1-29 primes the somatotroph by stimulating cAMP production, GHRP-6 induces an immediate influx of extracellular calcium ions alongside IP3-mediated calcium release from the endoplasmic reticulum. This combined intracellular stimulus prompts exocytosis of GH-containing secretory vesicles at rates significantly exceeding the mathematical sum of either compound administered in isolation.
Furthermore, co-stimulation assays reveal that this dual approach preserves natural pulsatile secretion profiles rather than inducing tonic, continuous GH elevation. Researchers monitoring pulsatility dynamics utilize this pairing to study natural endocrine rhythms without causing rapid receptor desensitization.
In addition to its somatotropic effects, GHRP-6 is widely investigated for its influence on central appetite signaling. Because GHRP-6 mimics the functional activity of endogenous ghrelin at the GHS-R1a receptor, it penetrates the blood-brain barrier in rodent models to interact directly with neurons within the arcuate nucleus of the hypothalamus.
In vitro hypothalamic brain slice preparations show that GHRP-6 binding stimulates Neuropeptide Y (NPY) and Agouti-Related Peptide (AgRP) expressing neurons while simultaneously inhibiting pro-opiomelanocortin (POMC) neurons. This neurochemical activation promotes orexigenic (appetite-stimulating) signaling, making GHRP-6 a valuable tool in preclinical studies focused on cachexia, metabolic dysregulation, and hyperphagic signaling pathways.
Researchers evaluating energy balance often compare the strong orexigenic response of GHRP-6 against other ghrelin mimetics that exhibit muted hypothalamic signaling. For detailed literature on individual secretagogue receptor profiles, explore our dedicated analysis on GHRP-6 mechanisms.
When designing somatotropic research protocols, investigators must select secretagogue combinations that align with specific analytical goals. The Mod GRF 1-29 & GHRP-6 combination is frequently benchmarked against other peptide pairs within the growth hormone secretagogue class to evaluate receptor affinity, appetite induction, and prolactin/cortisol co-stimulation.
For example, researchers seeking to minimize orexigenic signaling while maintaining potent secretagogue activity often evaluate Ipamorelin in place of GHRP-6, as Ipamorelin exhibits high selectivity for GHS-R1a without stimulating NPY pathways or elevating secondary hormones. Alternatively, studies requiring heightened secondary signal amplification may utilize GHRP-2, which demonstrates higher potency in GH release than GHRP-6 but lower appetite activation. When extended half-life dynamics are required without frequent administration intervals, investigators contrast short-acting Mod GRF 1-29 against long-acting analogues in our CJC-1295 DAC vs No DAC comparison.
The table below summarizes the key operational differences across these common preclinical secretagogue compounds:
To maintain molecular integrity during reconstitution, laboratory personnel should adhere to standardized aseptic techniques using non-pyrogenic reagents. Both Mod GRF 1-29 and GHRP-6 are supplied as lyophilized powders sealed under inert gas to prevent oxidative degradation.
Reconstitution should be performed using laboratory-grade Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl), depending on the requirements of the downstream assay. For cell-culture applications where benzyl alcohol may induce cytotoxicity, sterile phosphate-buffered saline (PBS, pH 7.4) is recommended for immediate use.
When introducing solvent into the vial, direct the stream along the glass wall rather than directly onto the lyophilized peptide cake. Gently swirl the vial in a circular motion until the cake dissolves completely. Never agitate or vortex the solution vigorously, as mechanical shear stress can cause peptide denaturing, aggregation, or precipitation. For high-volume laboratory acquisitions, research facilities can request specialized bulk quantities through our wholesale laboratory account portal.
Lyophilized Mod GRF 1-29 and GHRP-6 demonstrate optimal long-term stability when stored at -20°C to -80°C in a temperature-monitored freezer away from light. Under these conditions, the un-reconstituted peptide matrix remains stable for up to 24 months without significant loss of purity.
Once reconstituted into aqueous solution, peptides are subject to hydrolysis and enzymatic cleavage. Reconstituted solutions stored at 2°C to 8°C (refrigerated) should typically be utilized within 30 days when prepared with bacteriostatic water. If reconstituted in plain sterile water or PBS, aliquots should be used immediately or frozen to prevent micro-bacterial proliferation and peptide degradation.
Repeated freeze-thaw cycles must be strictly avoided. Freeze-thaw stress induces conformational changes and peptide aggregation, reducing effective concentration in binding assays. PX1 Research recommends partitioning reconstituted stock solutions into single-use micro-centrifuge tubes prior to initial freezing.
Scientific rigor demands that research peptides possess verified chemical purity, precise molecular mass, and freedom from biological contaminants. PX1 Research mandates third-party analytical verification for every production lot before release to academic and corporate laboratories.
Purity is quantified using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). Our threshold mandates that both Mod GRF 1-29 and GHRP-6 maintain a minimum chromatographic purity of 99.0%. Mass identity is verified via Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF), confirming that observed molecular weights strictly match theoretical monoisotopic masses.
In addition to chemical purity, endotoxin levels are measured using the Limulus Amebocyte Lysate (LAL) enzymatic assay. Ensuring endotoxin levels fall well below standard regulatory thresholds (<0.05 EU/mg) is critical for preventing artifactual inflammatory responses in primary cell cultures and animal models. Every order includes a lot-specific Certificate of Analysis (COA) linked directly to traceable synthesis records. All compounds are manufactured in USA-based, GMP-compliant facilities.
What is the primary rationale for combining Mod GRF 1-29 and GHRP-6 in preclinical research?
Mod GRF 1-29 acts as a GHRH receptor agonist, whereas GHRP-6 acts as a GHS-R1a (ghrelin) receptor agonist. In preclinical models, stimulating both pathways simultaneously yields a synergistic, supra-additive release of growth hormone that exceeds the sum of either peptide administered individually.
How does GHRP-6 differ from Ipamorelin in laboratory models?
While both compounds target the GHS-R1a receptor, GHRP-6 activates hypothalamic NPY/AgRP neurons, inducing significant appetite-signaling (orexigenic responses) and minor co-stimulation of ACTH/cortisol. Ipamorelin is highly selective for GH release without stimulating appetite pathways or secondary adrenal hormones.
What solvent is recommended for reconstituting Mod GRF 1-29 and GHRP-6 for long-term assay storage?
Bacteriostatic Water (0.9% benzyl alcohol) is recommended for multi-use laboratory storage at 2-8°C, providing stability up to 30 days. For immediate in vitro cell culture assays sensitive to preservatives, sterile phosphate-buffered saline (PBS) or sterile water should be used.
What analytical methods are used by PX1 Research to verify peptide purity?
PX1 Research utilizes Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) to verify chromatographic purity (minimum 99.0%), Mass Spectrometry (MS) to confirm exact molecular weight, and LAL assays to quantify endotoxin levels.
Can reconstituted Mod GRF 1-29 and GHRP-6 be frozen for future use?
Yes, reconstituted stock solutions can be aliquoted into single-use polypropylene tubes and frozen at -20°C or -80°C. However, repeated freeze-thaw cycles must be avoided to prevent peptide denaturing and loss of biological activity.
What is the half-life of Mod GRF 1-29 compared to native GHRH in serum assays?
Native GHRH (1-44) has an in vitro serum half-life of under 5 minutes due to rapid cleavage by DPP-IV. Mod GRF 1-29 contains four amino acid substitutions that increase its plasma stability to approximately 30 minutes in preclinical assays.
Are PX1 Research compounds manufactured in the United States?
Yes. All PX1 Research peptides are manufactured in USA-based, GMP-compliant facilities and undergo independent ISO 17025 laboratory testing with full lot-specific traceability.
What endotoxin threshold is maintained for PX1 secretagogue peptides?
PX1 Research enforces strict quality control standards, ensuring endotoxin levels remain below 0.05 EU/mg as verified by LAL assay testing, preventing baseline cellular toxicity or fever responses in laboratory models.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.